SCHEMBL24393197

SCHEMBL24393197

Clc1ncc(N2CCCCC2)c(Cl)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.41
POLB P06746 3/20 0.41
CHKA P35790 1/20 0.38
CNR2 P34972 2/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
MEN1 O00255 1/20 0.36
GFER P55789 1/20 0.36
KMT2A Q03164 1/20 0.36
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.36
ALOX15 P16050 2/20 0.36
HSD17B10 Q99714 2/20 0.36
NCF1 P14598 1/20 0.36
PKM P14618 1/20 0.36
CASP1 P29466 1/20 0.36
CYP1A2 P05177 1/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17269955 0.98 POLB (0.40) ALDH1A1POLBCHKACNR2SMN1; SMN2
SCHEMBL17225009 0.81 SMN1; SMN2 (0.57) POLBSMN1; SMN2KDM4E
SCHEMBL3767624 0.81 MAPK1 (0.42) CNR2SMN1; SMN2KDM4EALOX15NCF1
SCHEMBL30462012 0.81 SMN1; SMN2 (0.57) POLBSMN1; SMN2KDM4E
SCHEMBL1935919 0.73 SMN1; SMN2 (0.47) ALDH1A1CNR2SMN1; SMN2MEN1GFER
SCHEMBL23330864 0.73 CNR2 (0.36) ALDH1A1POLBCNR2MEN1KMT2A
SCHEMBL23330850 0.73 CNR2 (0.39) CNR2SMN1; SMN2
SCHEMBL1935622 0.71 SMN1; SMN2 (0.49) ALDH1A1SMN1; SMN2GFERKDM4EHSD17B10
SCHEMBL23331023 0.70 HSD17B10 (0.40) ALDH1A1CNR2SMN1; SMN2MEN1KMT2A
SCHEMBL24477793 0.70 SMN1; SMN2 (0.45) ALDH1A1SMN1; SMN2MEN1GFERKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240051945-A1 PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF BLUEPRINT MEDICINES CORPORATION 2024-02-15 US disclosed
EP-4237418-A1 PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF Blueprint Medicines Corporation (US) 2023-09-06 EP disclosed
CN-116685583-A Pyrimidine compounds, compositions and pharmaceutical uses thereof 缆图药品公司 2023-09-01 CN disclosed
WO-2022094354-A1 PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF LENGO THERAPEUTICS, INC. (US) 2022-05-05 WO disclosed
WO-2022094354-A1 PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF LENGO THERAPEUTICS, INC. (US) 2022-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240051945-A1 PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF TYMP, DPYD, TYMS ALDH1A1 963/4885POLB 91/4885CHKA 2010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.